Listed below are HCV-TARGET Study Group presentations at the 2013 annual meeting of the American Association for the Study of Liver Diseases. For abstracts, visit http://www.aasld.org/livermeeting.
Contact: Joy A. Peter, Project Manager, Joy.Peter@medicine.ufl.edu

DateTimeSession & LocationTitleAuthors
Saturday, Nov. 2, 20132:00 p.m. - 7:30 p.m.Behavioral and Practice Issues (Poster Hall)Poster Presentation (Control ID 1737671):325. Pre-Treatment Education and Treatment Completion in Patients with Hepatitis C (HCV) Treated with Boceprevir (BOC) or Telaprevir (TVR)Deborah A. Mercier, Brenda A. Appolo, Danielle E. Cardona, Andrea C. Scherschel, Patrick Horne, Sarah B. Hubbard, Lisa Richards, Andrea L. Keller, Thomas Stewart, Monika Vainorius, Joy A. Peter
Sunday, Nov. 3, 20133:45 p.m. - 4:00 p.m.Parallel 2: Epidemiology of Viral Hepatitis (Room 147)Oral Presentation (Control ID 1739724): 22. Impact of Age on Safety and Treatment Response in Patients with Hepatitis C (HCV) Treated With Boceprevir or TelaprevirAndrew Aronsohn, Tuesdae Stainbrook, Smruti Mohanty, Abdullah Mubarak, James Spivey, Prashant K. Pandya, Thomas Stewart, Michael W. Fried, Ira M. Jacobson
Sunday, Nov. 3, 20134:00 p.m. - 4:15 p.m.Parallel 5: HCV Therapeutics: Real World Experience (Hall E/ General Session)Oral Presentation (Control ID 1740346): 41. Virologic Outcomes and Adherence to Treatment Algorithms in a Longitudinal Study of Patients with Chronic Hepatitis C Treated with Boceprevir (BOC) or Telaprevir (TVR) in the United States (HCV-TARGET)Adrian M. Di Bisceglie, Alexander Kuo, Vinod K. Rustgi, Mark S. Sulkowski, Richard K. Sterling, Thomas Stewart, Michael W. Fried, Jonathan M. Fenkel, Hisham ElGenaidi, Mitchell A. Mah'moud, George M. Abraham
Tuesday, Nov. 5, 20138:00 a.m. - 12:00 p.m.HCV Therapeutics: Approved Agents (Poster Hall)Poster Presentation (Control ID 1741229): 1865. Safety and Efficacy of Telaprevir (TVR) or Boceprevir (BOC) in Patients with Cirrhosis: Interim Results of a Longitudinal, Observational StudyNezam H. Afdhal, Nancy Reau, Gregory T. Everson, Giuseppe Morelli, Anna S. Lok, Kenneth E. Sherman, Rolland C. Dickson, Fredric Regenstein, Edward A. Mena, Thomas Stewart, Michael W. Fried, Paul J. Pockros
Tuesday, Nov. 5, 20138:00 a.m. - 12:00 p.m.HCV Therapeutics: Approved Agents (Poster Hall)Poster Presentation (Control ID 1740645): 1866. The Frequency and Management of Adverse Events in Chronic Hepatitis C (HCV) Treated with Boceprevir or Telaprevir: Real World Experience from the HCV-TARGET Longitudinal Observational StudyStuart C. Gordon, Andrew J. Muir, Joseph K. Lim, Brian Pearlman, Curtis K. Argo, Guy W. Neff, Ananthakrishnan Ramani, Benedict Maliakkal, Maribel Rodriguez-Torres, Thomas Stewart, Michael W. Fried, K. Rajender Reddy